Genetic Test to Find Ovarian and Endometrial Cancer Early
Develops a genetic test for early ovarian and endometrial cancer detection.
Plain-language title generated from the registry record
Registry title: DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics
Key facts
- Where
- Montreal, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women who will have surgery: either for suspected or confirmed cancer of the upper genital tract, or a hysterectomy or tube removal for presumed benign disease.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Suspected or confirmed cancer of the upper genital tract, or presumed benign (not cancer) disease for the control group
Read by machine on 12 November 2026.
Where in Canada
- Royal Victoria Hospital (Glen Site)Montreal, CanadaContact: Dr. Lucy Gilbert, MD,MSc,FRCOGTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- McGill University
- Trial code
- NCT02288676
- Record updated
- 18 June 2025
- Original description
This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers from a uterine pap test. A saliva sample is also collected that acts as an internal control and has the ability to detect deleterious germline mutations associated with common hereditary cancers (such as breast, ovarian, endometrial, colon, and pancreatic cancers). A machine learning classifier is then used to discriminate between cancer and benign disease.Read full original descriptionShow less
DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics
This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers from a uterine pap test. A saliva sample is also collected that acts as an internal control and has the ability to detect deleterious germline mutations associated with common hereditary cancers (such as breast, ovarian, endometrial, colon, and pancreatic cancers). A machine learning classifier is then used to discriminate between cancer and benign disease.
Case Inclusion:; Subjects should have suspected or confirmed cancer of the upper genital tract; Participant will undergo surgery for tumour removal; Control inclusion:; Subjects should be scheduled to have a hysterectomy, bilateral salpingectomy, with or without bilateral oophorectomy, for presumed benign disease.